Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma
Synaptojanin 2 (SYNJ2) regulates cell proliferation and apoptosis via dephosphorylating plasma membrane phosphoinositides. Aim of this study is to first seek the full-scale expression levels and potential emerging roles of SYNJ2 in hepatocellular carcinoma (HCC). We systematically analyzed SYNJ2 mRNA expression and protein levels in HCC tissues based on large-scale data and in-house immunohistochemistry (IHC). The clinical significance and risk factors for SYNJ2-related HCC cases were identified. A nomogram of prognosis was created and its performance was validated by concordance index (C-index) and shown in calibration plots. Based on the identified differentially coexpressed genes (DCGs) of SYNJ2, enriched annotations and potential pathways were predicted, and the protein interacting networks were mapped. Upregulated SYNJ2 in 3,728 HCC and 3,203 non-HCC tissues were verified and in-house IHC showed higher protein levels of SYNJ2 in HCC tissues. Pathologic T stage was identified as a risk factor. Upregulated mRNA levels and mutated SYNJ2 might cause a poorer outcome. The C-index of the nomogram model constructed by SYNJ2 level, age, gender, TNM classification, grade, and stage was evaluated as 0.643 (95%CI = 0.619–0.668) with well-calibrated plots. A total of 2,533 DCGs were extracted and mainly functioned together with SYNJ2 in metabolic pathways. Possible transcriptional axis of CTCF/POLR2A-SYNJ2/INPP5B (transcription factor-target) in metabolic pathways was discovered based on ChIP-seq datasets. In summary, transcriptional regulatory axis CTCF/POLR2A-SYNJ2 might influence SYNJ2 expression levels. Increased SYNJ2 expression level could be utilized for predicting HCC prognosis and potentially accelerates the occurrence and development of HCC via metabolic perturbations pathways..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Bioengineered - 12(2021), 1, Seite 855-874 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rui Zhang [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Biotechnology |
|---|
| doi: |
10.1080/21655979.2021.1890399 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ078714818 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ078714818 | ||
| 003 | DE-627 | ||
| 005 | 20230503144731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230307s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21655979.2021.1890399 |2 doi | |
| 035 | |a (DE-627)DOAJ078714818 | ||
| 035 | |a (DE-599)DOAJef4e57add2e447abb2110b69af88e458 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a TP248.13-248.65 | |
| 100 | 0 | |a Rui Zhang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Synaptojanin 2 (SYNJ2) regulates cell proliferation and apoptosis via dephosphorylating plasma membrane phosphoinositides. Aim of this study is to first seek the full-scale expression levels and potential emerging roles of SYNJ2 in hepatocellular carcinoma (HCC). We systematically analyzed SYNJ2 mRNA expression and protein levels in HCC tissues based on large-scale data and in-house immunohistochemistry (IHC). The clinical significance and risk factors for SYNJ2-related HCC cases were identified. A nomogram of prognosis was created and its performance was validated by concordance index (C-index) and shown in calibration plots. Based on the identified differentially coexpressed genes (DCGs) of SYNJ2, enriched annotations and potential pathways were predicted, and the protein interacting networks were mapped. Upregulated SYNJ2 in 3,728 HCC and 3,203 non-HCC tissues were verified and in-house IHC showed higher protein levels of SYNJ2 in HCC tissues. Pathologic T stage was identified as a risk factor. Upregulated mRNA levels and mutated SYNJ2 might cause a poorer outcome. The C-index of the nomogram model constructed by SYNJ2 level, age, gender, TNM classification, grade, and stage was evaluated as 0.643 (95%CI = 0.619–0.668) with well-calibrated plots. A total of 2,533 DCGs were extracted and mainly functioned together with SYNJ2 in metabolic pathways. Possible transcriptional axis of CTCF/POLR2A-SYNJ2/INPP5B (transcription factor-target) in metabolic pathways was discovered based on ChIP-seq datasets. In summary, transcriptional regulatory axis CTCF/POLR2A-SYNJ2 might influence SYNJ2 expression levels. Increased SYNJ2 expression level could be utilized for predicting HCC prognosis and potentially accelerates the occurrence and development of HCC via metabolic perturbations pathways. | ||
| 650 | 4 | |a synaptojanin 2 | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a nomogram predicting | |
| 650 | 4 | |a differentially coexpressed genes | |
| 650 | 4 | |a metabolism | |
| 653 | 0 | |a Biotechnology | |
| 700 | 0 | |a Wei-Jia Mo |e verfasserin |4 aut | |
| 700 | 0 | |a Lan-Shan Huang |e verfasserin |4 aut | |
| 700 | 0 | |a Ji-Tian Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Wei-Zi Wu |e verfasserin |4 aut | |
| 700 | 0 | |a Wei-Ying He |e verfasserin |4 aut | |
| 700 | 0 | |a Zhen-Bo Feng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Bioengineered |d Taylor & Francis Group, 2019 |g 12(2021), 1, Seite 855-874 |w (DE-627)DOAJ000094374 |x 21655987 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:1 |g pages:855-874 |
| 856 | 4 | 0 | |u https://doi.org/10.1080/21655979.2021.1890399 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ef4e57add2e447abb2110b69af88e458 |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21655979.2021.1890399 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2165-5979 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2165-5987 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 1 |h 855-874 | ||